SOURCE: BioBlocks, Inc.

July 31, 2008 08:15 ET

BioBlocks Forms International Drug Discovery Team, Representing a New Generation Pre-Clinical CRO

SAN DIEGO, CA--(Marketwire - July 31, 2008) - BioBlocks, Inc., leading provider of chemical building blocks and drug discovery chemistry outsourcing, today announced a significant expansion of its international management team, which is focused on capital efficient, results-driven chemistry for lead optimization. The US team, which is closely tied to the latest drug discovery research and technology, will continue to interface closely with a highly trained team of scientists based in Hungary. To ensure seamless integration and continued focus on strong, goal-oriented project management, BioBlocks has added Warren Wade, Ph.D., Director of Medicinal Chemistry, BioBlocks USA, and Katalin Gero, M.A., General Manager of BioBlocks Hungary. These new additions will work closely with Peter Pallai, Ph.D., CEO of BioBlocks USA, and Laszlo Urogdi, Ph.D., Director of Medicinal Chemistry, BioBlocks Hungary. Together, they form a team that is well positioned to meet the needs of pharmaceutical companies who are turning increasingly to contract research organizations (CRO) to minimize overhead and cut costs. By focusing on meeting drug discovery program metrics, and utilizing an integrated international team, BioBlocks represents a new generation of drug discovery CROs which will augment pharmaceutical pipelines with intelligent and cost effective manpower.

Warren Wade, Ph.D., Director of Medicinal Chemistry, BioBlocks USA, has experience advancing two small molecule candidates for Investigational New Drug (IND) filings while a Director of Medicinal Chemistry at Neurocrine Biosciences, Inc. The leading candidate is currently in Phase 2 trials for endocrine indications. He was also involved in the discovery of other preclinical compounds for obesity, acute and neuropathic pain, multiple sclerosis, and insomnia indications. In this role, Dr. Wade managed interdisciplinary drug discovery teams, timelines, and project goals. During his time at Neurocrine he worked on lead discovery and optimization for multiple classes of targets including GPCRs, ion channels and molecular transporters. Prior to this, Dr. Wade was a Research Investigator at Abbott where he was involved in developing their combinatorial chemistry program to maturity, worked with the Abbott Fragment Based Lead Discovery group, and gained experience with parallel synthesis. Dr. Wade brings his first-hand experience in the application of new technologies for lead optimization and his goal-oriented program management skills to BioBlocks' international team. Working with Dr. Laszlo Urogdi at BioBlocks Hungary, the two will effectively guide BioBlocks' lead optimization collaborations with a strong emphasis on medicinal chemistry.

Katalin Gero, in her new role as General Manager of BioBlocks Hungary, will oversee its daily operations, forge a seamless transition during a time of aggressive growth, and coordinate communication with BioBlocks USA. Her significant management, logistics, and business experience is vital to implementing project plans that meet pharmaceutical client needs. Formerly, as the Director of Commerce at Izinta Trading Co., Ms. Gero launched oncology and brachytherapy (sealed source radiotherapy) medical devices and software onto the Hungarian market. In addition, she had P&L responsibilities and effectively liaised internal and external groups towards mutually beneficial objectives. She was previously at ICN Hungary where she managed bulk exports and improved sales of their morphine products worldwide. Ms. Gero's extensive expertise interfacing international pharmaceutical business with the management of talented scientific teams is a strong complement to the BioBlocks international team.

Peter Pallai, Ph.D., CEO and founder of BioBlocks, and a medicinal chemist with 23 years of drug discovery experience, commented, "The addition of Dr. Wade and Ms. Gero to our international team confirms BioBlocks' commitment to providing the most advanced and efficient drug discovery services to our clients. Our results-based, hit to lead chemistry technologies and expertise cover a broad range of therapeutic areas, and we look forward to working with companies who are looking to leverage capital efficient resources to strengthen their drug discovery portfolios."

About BioBlocks

BioBlocks, Inc. was founded in San Diego, CA, in 2002 to provide chemistry services and specialty building blocks to the drug discovery community. Over the past six years, the company has been transformed into a leading provider of medicinal chemistry services. BioBlocks also offers more than 1500 chemistry building blocks for drug discovery, including quinolines, benzylpiperidines, and Beta-amino acids.

Contact Information

  • Contact:
    Dr. Peter Pallai
    CEO
    BioBlocks
    phone: (858) 558-5900